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Abstract: The glucagon-like peptide-1 receptor (GLP-1R) is an important regulator of blood glucose
homeostasis. Ligand-specific differences in membrane trafficking of the GLP-1R influence its signalling
properties and therapeutic potential in type 2 diabetes. Here, we have evaluated how different factors
combine to control the post-endocytic trafficking of GLP-1R to recycling versus degradative pathways.
Experiments were performed in primary islet cells, INS-1 832/3 clonal beta cells and HEK293 cells,
using biorthogonal labelling of GLP-1R to determine its localisation and degradation after treatment
with GLP-1, exendin-4 and several further GLP-1R agonist peptides. We also characterised the effect
of a rare GLP1R coding variant, T149M, and the role of endosomal peptidase endothelin-converting
enzyme-1 (ECE-1), in GLP1R trafficking. Our data reveal how treatment with GLP-1 versus exendin-4 is
associated with preferential GLP-1R targeting towards a recycling pathway. GLP-1, but not exendin-4,
is a substrate for ECE-1, and the resultant propensity to intra-endosomal degradation, in conjunction
with differences in binding affinity, contributes to alterations in GLP-1R trafficking behaviours and
degradation. The T149M GLP-1R variant shows reduced signalling and internalisation responses,
which is likely to be due to disruption of the cytoplasmic region that couples to intracellular effectors.
These observations provide insights into how ligand- and genotype-specific factors can influence
GLP-1R trafficking.
Int. J. Mol. Sci. 2020, 21, 8404; doi:10.3390/ijms21218404 www.mdpi.com/journal/ijms
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1. Introduction
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR)
with pleiotropic roles in glucose homeostasis and energy metabolism [1]. Well-characterised effects of
GLP-1R activation include augmentation of glucose-stimulated insulin secretion from pancreatic beta
cells, suppression of appetite and slowing of gastric emptying. These actions have been harnessed
therapeutically for the treatment of type 2 diabetes (T2D) and obesity, with several pharmacokinetically
optimised GLP-1R agonists now in routine clinical use [2]. Further applications of GLP-1R agonism
have been proposed, including treatment of steatohepatitis [3] and neurodegenerative diseases [4].
Whilst in vitro optimisation of GLP-1R ligands has traditionally focussed on high binding
affinity or signalling potency, recent work has highlighted that the balance between recruitment of
signal-initiating versus signal-terminating effectors can allow low-affinity “biased” GLP-1R agonists to
achieve high therapeutic efficacy [5–8]. Connected to this, agonist-specific trafficking patterns of the
GLP-1R between different endomembrane compartments allow fine-tuning of the duration and spatial
origin of intracellular signalling responses [9–12].
Therapeutic GLP-1R peptide ligands are typically based on the sequence of either the primary
endogenous agonist, GLP-1(7-36)-NH2, or its homologue exendin-4, a 39 amino acid peptide isolated
originally from the venom of the Gila monster [13]. Whilst these are both high-potency full agonists
at the GLP-1R, a number of studies have reported differential signal bias and altered trafficking
characteristics of these core ligands [11,14–16]. In particular, recycling of internalised GLP-1R back to
the plasma membrane is slower after exendin-4 treatment, resulting in more pronounced desensitisation
in challenge/washout/re-challenge experiments [11,15,17]. The reasons for these differences have not
been fully elucidated, but it has been suggested that the trafficking behaviours of GLP-1R ligands may
relate to either intra-endosomal ligand-receptor dissociation [6] or to differential ligand sensitivity
to intra-endosomal degradation by the endopeptidase endothelin converting enzyme-1 (ECE-1) [18].
Many prior studies have been performed using GLP-1R expressed in heterologous systems and,
with increasing recognition that GPCR behaviours can be tissue-specific [19], their findings ideally
should be confirmed using beta cell models.
In this study, we have explored the post-endocytic sorting of GLP-1R after treatment with
GLP-1 or exendin-4. We focus in particular on ligand-specific differences in receptor degradation,
which may in turn contribute to receptor availability and insulin secretory responses during prolonged
pharmacological stimulation. We investigate the importance of intra-endosomal ligand proteolysis
by ECE-1 through the use of pharmacological inhibition and a panel of chimeric peptide ligands
with varying degrees of ECE-1 resistance. We further dissect this phenomenon from the contribution
of binding affinity and β-arrestin recruitment by concurrently testing derivatives of these peptides
bearing N-terminal substitutions. Finally, we examine the trafficking responses of a natural GLP-1R
variant, T149M, previously associated with T2D [20] and known to show impaired intracellular cyclic
adenosine monophosphate (cAMP) signalling responses [21].
2. Results
2.1. GLP-1R Degradation in Beta Cells is More Prominent after Treatment with Exendin-4 versus GLP-1
GLP-1R is typically described as a fast-internalising receptor [22]. To provide evidence that this is the
case for endogenous GLP-1R in its native cellular context, we first visualised uptake of fluorescent GLP-1
and exendin-4 conjugates (see Supplementary Figure S1) in dispersed primary islet cells, with GLP-1R
expression marked by the fluorescent reporter GCaMP3 under Cre-dependent control [23] (Figure 1A).
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Both ligands were extensively taken up into punctate endosome-like structures. As agonist and receptor
may dissociate on entering the endocytic pathway, to study the post-endocytic trafficking of GLP-1R in a
beta cell context we used cultured INS-1 832/3 cells stably expressing N-terminally SNAP-tagged GLP-1R
(referred to hereafter as INS-1-SNAP-GLP-1R cells) [24]. A cleavable benzyl guanine (BG)-conjugated
fluorescent probe, BG-S-S-649, allowed quantification of internalised and subsequently recycled
SNAP-GLP-1R by high content microscopy, as previously described [11]. Pronounced GLP-1R
internalisation was observed with both ligands at high concentrations, with exendin-4 showing
slightly increased potency (Figure 1B). Moreover, following agonist washout, GLP-1R recycled more
slowly after exendin-4 treatment over a wide concentration range. We also visualised post-endocytic
sorting of SNAP-GLP-1R by electron microscopy after treatment with either ligand in MIN6 mouse
beta cells, with the receptor surface-labelled using BG-biotin and streptavidin-gold prior to treatment.
This indicated a trend towards greater localisation of GLP-1R in late endosomes and lysosomes after
exendin-4 treatment compared to GLP-1 (Figure 1C).Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 24 
 
 
Figure 1. Accelerated GLP-1R degradation with exendin-4 in beta cells. (A) Endocytic uptake of 100 
nM GLP-1-TMR or exendin-4-TMR in GLP-1R-expressing dispersed primary islet cells. GLP-1R-
positive cells are marked by GCaMP3 under GLP-1R promoter-driven Cre expression. Representative 
images from n = 2 mice. Scale bar = 6 µm. The sequences and pharmacological characterisation of 
GLP-1-TMR and exendin-4-TMR are provided in the Supporting Information (Supplementary Figure 
S1). (B) Assessment of GLP-1R trafficking in INS-1-SNAP-GLP-1R cells using high content 
microscopy. Representative images and quantification of GLP-1R internalisation (30 min) and 
recycling (60 min) from n = 5 experiments is shown, with internalisation pEC50 compared by paired t-
test, and recycling results compared by two-way randomised block ANOVA with Sidak’s test. Scale 
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GLP-1-TMR or exendin-4-TMR in GLP-1R-expressing dispersed primary islet cells. GLP- positive
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cells are marked by GCaMP3 under GLP-1R promoter-driven Cre expression. Representative images
from n = 2 mice. Scale bar = 6 µm. The sequences and pharmacological characterisation of
GLP-1-TMR and exendin-4-TMR are provided in the Supporting Information (Supplementary Figure S1).
(B) Assessment of GLP-1R trafficking in INS-1-SNAP-GLP-1R cells using high content microscopy.
Representative images and quantification of GLP-1R internalisation (30 min) and recycling (60 min) from
n = 5 experiments is shown, with internalisation pEC50 compared by paired t-test, and recycling results
compared by two-way randomised block ANOVA with Sidak’s test. Scale bar = 30 µm. (C) Example
electron micrographs in MIN6B1-SNAP-GLP-1R cells labelled with BG-S-S-biotin and streptavidin-gold
(10 nm) and treated with 100 nM exendin-4 and GLP-1 for 1 h. Quantification of gold particle distribution
from n = 3 experiments comprising plasma membrane (PM), early endosomes (EE), multivesicular body
limiting membrane (MVB LM) or intraluminal vesicles (ILV), recycling endosomes or tubules (Tub/RE)
and late endosomes or lysosomes (LE/Lyso). Scale bar = 1 µm. (D) Time-course for GLP-1R degradation
in INS-1-SNAP-GLP-1R cells treated with cycloheximide (50 µg/mL) in serum-free medium ± 10 nM
agonist, applied in reverse time order, followed by BG-OG labelling (0.5 µM) for the final 30 min of the
study. Representative images and quantification from n = 4 experiments are shown, with t1/2 quantified
by 1-phase exponential curve fitting and compared by paired t-test. Scale bar = 50 µm. (E) Western
blot analysis and quantification of GLP-1R degradation in INS-1-SNAP-GLP-1R cells after treatment
for 6 h in serum-free medium supplemented with 50 µg/mL cycloheximide in the presence or absence
of 10 nM GLP-1 or exendin-4, quantification from n = 4 experiments and comparison by paired t-test.
(F) GLP-1R degradation in INS-1-SNAP-GLP-1R cells pre-treated with cycloheximide (50 µg/mL) in
serum-free medium for 60 min before application of agonist for 30 min, followed by washout and
4 h incubation; 3-parameter fit of data from n = 5 experiments. * p < 0.05 by statistical test indicated.
Data represented as mean ± SEM.
To examine the consequences of these apparent differences in post-endocytic sorting on GLP-1R
degradation, experiments were performed in INS-1-SNAP-GLP-1R cells treated with cycloheximide to
arrest protein translation. After continuous exposure to 10 nM of either ligand, applied in a time series in
reverse order, a cell permeating SNAP-tag probe, BG-conjugated Oregon Green (BG-OG) [25], was used
to label total residual intact SNAP-GLP-1R. Over an 8 h time-course, a steady reduction of BG-OG
labelling was apparent with both ligands, suggesting destruction of the SNAP moiety (and by inference,
the GLP-1R itself), but this was faster and more pronounced with exendin-4 treatment (Figure 1D).
Note that BG-OG labelling of internalised SNAP-GLP-1R after 30 min treatment with 100 nM agonist
was similar for both agonists, suggesting that the fluorescent signal reduction seen in Figure 1D did
not represent the effect of endosomal pH on fluorophore emission intensity per se (Supplementary
Figure S2). Moreover, densitometric Western blotting analysis following 6 h stimulation with 10 nM
agonists in INS-1-SNAP-GLP-1R cells confirmed greater SNAP-GLP-1R degradation with exendin-4
(Figure 1E). Additionally, 4 h after a 30 min pulsed agonist treatment and washout, loss of GLP-1R
signal was more pronounced throughout the concentration range tested with exendin-4 compared
to GLP-1 (Figure 1F). Because residual extracellular agonist was removed in the latter experiment,
the result is likely to represent the differential effects of internalised GLP-1R-exendin-4 versus -GLP-1
complexes on post-endocytic targeting.
2.2. GLP-1R Degradation Rates are Associated with Ligand Sensitivity to ECE-1
It was recently reported that GLP-1R trafficking in HEK293 cells is regulated by the activity of
ECE-1 [18], a pH-sensitive endopeptidase known to degrade various GPCR peptide ligands once
they enter the endocytic system. The resultant dissociation of the ligand-receptor complex typically
prompts preferential targeting of the receptor to a recycling pathway [26,27]. Due to the known
differences in proteolytic stability of GLP-1 versus exendin-4 to the related neutral endopeptidase
NEP24.11 [28], we aimed to experimentally verify whether ECE-1 sensitivity might underpin the
observed differences in post-endocytic sorting with these two ligands in beta cells. We first performed
in vitro digestion assays of GLP-1 using ECE-1 and ECE-2 under neutral and acidic pH conditions,
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to mimic the extracellular and intra-endosomal environments, respectively. Here, high performance
liuid chromatography (HPLC) measurements indicated extensive peptide degradation, particularly by
ECE-1 at low pH (Figure 2A). Exendin-4 was highly resistant to ECE-1 and ECE-2 degradation,
remaining entirely intact after a 24 h incubation with either enzyme at low pH (Figure 2B).
To determine the importance of ECE-1-mediated agonist degradation on post-endocytic
GLP-1R sorting, we used the specific ECE-1 inhibitor SM-19712 [18,26,29], which inhibited ECE-1
activity in INS-1-SNAP-GLP-1R cells by approximately 60% when applied at 10 µM (Figure 2C).
Under these conditions, reduced degradation of ECE-1-sensitive GLP-1 is expected to result in greater
targeting of GLP-1R towards a degradative pathway, without affecting responses to ECE-1-resistant
exendin-4. Indeed, treatment with SM-19712 for 4 h after exposure to GLP-1 led to a two-fold
increase in potency for GLP-1R degradation, without affecting the response to exendin-4 (Figure 2D).
However, even in the presence of SM-19712, exendin-4 remained five-fold more potent for GLP-1R
degradation, suggesting that ECE-1 sensitivity is unlikely to be the only reason for the differential
GLP-1R degradative potential of these two ligands.
We also performed further studies using a series of chimeric peptides sharing features of GLP-1 and
exendin-4 (Figure 2E), which we recently reported to show divergent effects on GLP-1R recycling [11].
In the present study, we measured breakdown of each of these ligands by ECE-1 in acidic conditions
(Figure 2F), finding that certain exendin-4-like features are important in conferring resistance to
ECE-mediated proteolysis. Of note, removal of the exendin-4 C-terminal “Trp-cage” to generate
exendin-4(1-30) led to a partial reduction in ECE-1 resistance, as previously noted with NEP24.11 [30].
Correspondingly, addition of the Trp-cage to the C-terminus of GLP-1 (generating “Chi1”) resulted in
a partial increase in ECE-1 resistance. As expected, substitution of A→G at position two of GLP-1,
which confers resistance to the exopeptidase dipeptidyl dipeptidase-4 (DPP-4), had no effect on
ECE-1 sensitivity.
Using these ligands, we observed variable degrees of GLP-1R degradation in INS-1-SNAP-GLP-1R
cells 4 h after pulsed treatment. ECE-1-sensitive peptides (GLP-1, GLP-1-G2, Chi1) tended to result in
less GLP-1R degradation than did the most ECE-1-resistant agonists (exendin-4, Chi2, Chi3) (Figure 2G).
Moreover, the relative ability of ECE-1 inhibition using SM-19712 to increase GLP-1R degradation was
somewhat more marked for the ECE-1-sensitive peptides, with the relationship between these two
factors depicted in Figure 2H.
These findings provide further support for a role, albeit a partial one, of ECE-1 in control of
post-endocytic targeting of GLP-1R in beta cells.
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Figure 2. GLP-1R degradation is partly influenced by ECE-1-mediated ligand proteolysis. (A) In vitro
GLP-1 degradation at indicated pH in the presence of 0.25 µg ECE-1 or ECE-2, determined by HPLC
quantification from n = 3 experiments. (B) Time-course of in vitro GLP-1 versus exendin-4 degradation
by ECE-1 or ECE-2 at pH 5.5, quantified from n = 2 experiments by HPLC. (C) ECE-1 activity measured
from INS-1-SNAP-GLP-1R cell lysates ± 10 µM SM-19712, n = 3, compared by paired t-test. (D) GLP-1R
degradation in INS-1-SNAP-GLP-1R cells pre-treated with cycloheximide (50 µg/mL) in serum-free
medium for 60 min before application of agonist for 30 min, followed by washout and 4 h incubation
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with serum-free medium containing cycloheximide ± 10 µM SM-19712; 3-parameter fit of data from
n = 5 experiments, with pEC50 compared by 2-way randomised block ANOVA with Sidak’s test.
(E) Schematic showing amino acid sequences of chimeric peptides, with GLP-1-derived sequences
in grey and exendin-4-derived sequences in red. (F) Time-course of in vitro degradation of chimeric
peptides by ECE-1 at pH 5.5, quantified from n = 3 experiments by HPLC. (G) GLP-1R degradation in
INS-1-SNAP-GLP-1R cells pre-treated with cycloheximide (50 µg/mL) in serum-free medium for 60 min
before application of 100 nM chimeric peptide for 30 min, followed by washout and 4 h incubation
with serum-free medium containing cycloheximide ± 10 µM SM-19712, n = 5, compared by 2-way
randomised block ANOVA with Sidak’s test. (H) Analysis of interaction between ECE-1 sensitivity as
indicated in (F) and additional GLP-1R degradation ± SM-19712 treatment as shown in (G). * p < 0.05
by statistical test indicated. Data represented as mean ± SEM.
2.3. Peptide Agonist N-Terminal Substitutions Influence GLP-1R Degradation
Ligand binding affinity is a further factor that influences post-endocytic receptor sorting,
achieved by controlling the stability of internalised ligand-receptor complexes [6,11,31]. Our earlier
work has highlighted how a His→ Phe amino acid substitution at position 1, and a Glu→ Asp switch
as position 3, tend to oppositely influence a number of pharmacological parameters of GLP-1R peptide
ligands, including binding affinity, signal bias, GLP-1R palmitoylation and lipid raft clustering [6,11,24].
Thus, asp3 and phe1 derivatives of the chimeric peptide panel in Figure 2 provide means to probe the
role of further factors beyond proteolytic stability in the control of ligand-induced GLP-1R degradation.
We have performed a prior evaluation of some of the phe1 ligands in an earlier work [11], using different
experimental conditions and analytical approaches.
Competition binding experiments in HEK293-SNAP-GLP-1R cells demonstrated a wide range of
binding affinities for this ligand panel (Figure 3A, Table 1). The phe1 substitution tended to decrease
affinity, whereas the asp3 modification had the opposite effect in some (but not all) cases. Efficacy for
β-arrestin-2 recruitment, a parameter commonly associated with GPCR endocytosis, was assessed
in HEK293 cells using nanoBiT complementation [7,32], with phe1 ligands showing attenuated
responses, as expected (Figure 3B, Table 1). GLP-1R endocytosis and recycling were assessed in
INS-1-SNAP-GLP-1R cells, as was GLP-1R degradation after pulsed agonist treatment and washout
(Figure 3C, Table 1). Treatment with phe1 ligands, in keeping with the well-established trafficking
pattern typically seen with this N-terminal substitution, was characterised by slow internalisation,
rapid recycling and a lower degree of GLP-1R degradation. Asp3 ligands tended to lead to somewhat
reduced GLP-1R recycling, as well as to increased degradation with the more GLP-1-like peptides.
The pharmacological effects of the full set of ligands are also summarised by heatmap representation
in Figure 3D, in which the degradation result has also been normalised to the previously determined
internalisation results to allow easier visual comparison of GLP-1R targeting towards recycling
versus degradation. Finally, using principal component analysis to identify ligand similarity after
dimensionality reduction from multiple pharmacological metrics, it was apparent that phe1 ligands
were most dissimilar to the others, with asp3 peptides also differentiated from his1 equivalents in
principal component 1 (PC1) (Figure 3E).
As the phe1 and asp3 substitutions are distant from the putative endopeptidase target zone,
these findings highlight how further ligand factors beyond ECE-1 susceptibility influence the
degradation of internalised GLP-1R.
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Table 1. Summary of agonist characteristics. Data are represented as mean ± SEM from n = 6 (binding affinity and degradation), n = 5 (internalisation and recycling)
or n = 4 (β-arrestin-2 recruitment) independent experiments.
Assay N-Terminus GLP-1 Chi1 Chi2 Chi3 Ex4(1-30) Ex4 GLP-1-G2
Log Ki (M)
H1 −7.6 ± 0.1 −8.2 ± 0.1 −8.4 ± 0.1 −9.1 ± 0.0 −9.0 ± 0.0 −9.5 ± 0.1 −7.0 ± 0.1
F1 −6.4 ± 0.1 −6.4 ± 0.1 −6.5 ± 0.0 −7.8 ± 0.1 −7.5 ± 0.0 −7.3 ± 0.1 −6.1 ± 0.0
D3 −8.0 ± 0.1 −8.5 ± 0.1 −9.0 ± 0.1 8.6 ± 0.1 −9.2 ± 0.1 −9.2 ± 0.1 −7.6 ± 0.1
β-arrestin-2 recruitment (AUC)
H1 6.2 ± 0.9 7.0 ± 1.6 8.4 ± 2.3 8.9 ± 2.1 4.0 ± 0.5 10.2 ± 1.6 1.3 ± 0.5
F1 2.0 ± 1.3 2.0 ± 0.8 4.6 ± 1.6 4.8 ± 1.4 0.8 ± 0.2 1.3 ± 1 0.9 ± 0.5
D3 4.9 ± 0.9 9.4 ± 0.5 8.1 ± 1.2 8.9 ± 1.4 8.8 ± 0.3 8.3 ± 0.3 4.0 ± 0.7
Internalisation (%)
H1 69.6 ± 14.1 88.9 ± 12.7 97.3 ± 14.3 93 ± 13.7 84.5 ± 17.4 110.7 ± 9.9 58.9 ± 11.4
F1 28.1 ± 11.1 18.5 ± 8.7 24.4 ± 9.3 40.6 ± 19.4 29.1 ± 11.3 25.5 ± 11.8 12.7 ± 7.8
D3 88.5 ± 16.9 97.7 ± 14.1 78.6 ± 15.7 101.5 ± 12.2 98 ± 12.3 105.4 ± 11.7 60.3 ± 17
Recycling (% internalised GLP-1R)
H1 44.1 ± 3.1 35.3 ± 2.8 30.9 ± 3.2 21.8 ± 3.8 26.4 ± 2.8 20.8 ± 3.6 44.4 ± 3.8
F1 55.2 ± 3.4 48.7 ± 4.8 48.5 ± 5.2 40.7 ± 2.7 45.9 ± 3.6 49.9 ± 3.2 62.7 ± 17.9
D3 33.2 ± 4.1 28.6 ± 4.0 22.9 ± 5.1 19.0 ± 4.3 19.2 ± 3.2 19.0 ± 3.5 35.4 ± 5.6
Degradation (% remaining GLP-1R)
H1 80.4 ± 2.7 72.9 ± 1.6 69.1 ± 5.7 52.8 ± 5.9 57.0 ± 5.3 52.6 ± 6.6 86.2 ± 5.5
F1 96.4 ± 6.7 95.6 ± 2 92.8 ± 4.5 77.1 ± 6.6 91.8 ± 6.4 99.3 ± 5.0 102.8 ± 4.7
D3 58.9 ± 4.4 62.9 ± 3.8 51.3 ± 8.1 51.8 ± 7.7 51.9 ± 7.1 55.0 ± 4.2 62.2 ± 7.7
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substituted GLP-1R agonists. (A) TR-FRET equilibrium binding affinity assays performed in
HEK293-SNAP-GLP-1R cells, with saturation binding of exendin(9-39)-FITC (“Ex9-FITC”) and effect of
indicated unlabelled agonist on binding of 10 nM exendin(9-39)-FITC in parallel experiments, n = 6.
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(B) β-arrestin-2 recruitment to GLP-1R in HEK293T cells, measured using nanoBiT complementation,
with 100 nM of indicated agonist, n = 4. (C) GLP-1R degradation in INS-1-SNAP-GLP-1R cells
pre-treated with cycloheximide (50 µg/mL) in serum-free medium for 60 min before application
of 100 nM peptide for 30 min, followed by washout and 4 h incubation with serum-free medium
containing cycloheximide, n = 6, with representative images provided. (D) Heatmap summarising
the pharmacological properties of each agonist at 100 nM, displayed as log2 fold difference after
normalisation to GLP-1 response. Occupancy has been inferred from the agonist Ki using the law of
mass action. (E) Principal component analysis of -his1, -phe1 and -asp3 ligands, with 2D plot showing
PC1 versus PC2 with loadings indicated on the axes, and violin plot indicating PC1-5 with comparison
within each component by randomised block one-way ANOVA with Dunnett’s test versus -his1 ligand.
* p < 0.05 by statistical test indicated. Data represented as mean ± SEM.
2.4. A Natural GLP-1R Variant Shows Altered Trafficking Response
GLP-1R-T149M is a rare GLP-1R single nucleotide coding variant (rs367543060) originally identified
in a T2D patient cohort [20]. Impaired signalling responses have been described for this variant [21,33],
as well as reduced internalisation in response to GLP-1 [34]. We used the Flp-In T-REx system to achieve
isogenic, tetracycline-inducible expression of wild-type and T149M variant GLP-1R, with both receptor
types SNAP-tagged at the N-terminus and bearing a SmBiT tag at the C-terminus. Surface localisation
of each receptor type after tetracycline induction was similar (Figure 4A), consistent with earlier
reports [33,34].
Exendin-4 coupled at the C-terminus to the far-red fluorophore Cy5 using cysteine-maleimide
conjugation (see Supplementary Figure S1), as previously performed using the antagonist ligand
exendin(9-39) [35], was used to evaluate ligand binding kinetics. GLP-1R-T149M showed a
modestly increased dissociation rate, which translated to a small reduction in affinity (Figure 4B).
However, there was a dramatic loss in exendin-4-induced recruitment of mini-Gs [36] and
β-arrestin-2 [32] with the T149M variant, as assessed by nanoBiT complementation (Figure 4C),
suggesting a pronounced signalling deficit. Indeed, potency for cAMP production was reduced
20-fold, with efficacy also reduced (Figure 4D). GLP-1R internalisation, visualised in parallel with
exendin-4-Cy5 endocytic uptake, was reduced with T149M (Figure 4E). Endocytosis and recycling
were further quantified by high content microscopy, which showed that maximum internalisation was
reduced by approximately 50%, accompanied by a potency reduction comparable to that observed for
cAMP production (Figure 4F). Correspondingly, GLP-1R recycling was modestly increased. GLP-1R
degradation by prolonged incubation with exendin-4 was assessed after first washing out tetracycline
to halt ongoing transcription of GLP-1R. In keeping with the results of the prior trafficking assay,
this indicated delayed degradation of T149M compared to wild-type over an 8 h time-course (Figure 4G).
Finally, we aimed to better understand the signalling and trafficking defect observed with
GLP-1R T149M by analysis of GLP-1R structures described in the literature. As the exendin-4-bound
GLP-1R structure has not been reported, we examined two full-length GLP-1R active structures
bound by different orthosteric agonists (exendin-P5 and GLP-1), both complexed with the Gs protein
heterotrimer [37,38]. T149 is a highly conserved residue located in the first transmembrane helix
(TM1) of GLP-1R (Figure 5A). The polar T149 residue is positioned towards the extracellular side
of the membrane and stabilizes the tilt of the TM1 helix by establishing a network of intrahelical
hydrogen bonds (Figure 5B, Supplementary Figure S3A). Although not directly involved in binding
to exendin-P5 or GLP-1, T149 is located in close proximity to the ligand binding pocket (Figure 5A,
Supplementary Figure S3A). Substitution of the polar threonine with the hydrophobic methionine is
predicted to affect GLP-1R conformation via disruption of the intrahelical hydrogen bond network.
This is likely to result in a change in the TM1 tilt, with possible displacement of residues located towards
the intracellular side of the membrane, where interaction with G proteins occurs (Figure 5C) [39],
a prediction that is consistent with our observation of reduced mini-Gs coupling with GLP-1R-T149M.
Whilst the position of β-arrestin complexed to GLP-1R has not been reported, structural analysis of
another GPCR-β-arrestin complex [40] suggests that the intracellular loop 1 (ICL1) of GLP-1R is likely
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to be involved in a complex network of physico-chemical interactions between GLP-1R and β-arrestin
(Supplementary Figure S3B). It can therefore be hypothesized that the conformational changes induced
by T149M may affect correct coupling of these two proteins to GLP-1R. In addition, introduction of
the large hydrophobic side chain of methionine results in a more favourable GLP-1R interaction with
the lipid bilayer, thus providing additional driving forces for TM1 helix tilting, as observed for other
GPCRs [41]. Introduction of this large hydrophobic residue results in increased thermostability, with an
overall stabilizing effect on GLP-1R protein (free energy change ∆∆G + 3 kcal/mol, confirmed with both
experimental GLP-1R structures analysed). This is likely to reduce GLP-1R intrinsic flexibility [42],
thereby resisting transition to an active receptor conformation on agonist binding.
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Figure 4. Trafficking and signalling with the T149M GLP-1R variant. (A) Tetracycline-induced expression
of wild-type and T149M SNAP-GLP-1R in stably transfected Flp-In 293-T-REx cells, with quantification
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from n = 5 experiments; scale bar = 30 µm. (B) Assessment of kinetic binding parameters of
exendin-4-C39-Cy5 in 293-T-Rex-GLP-1R cells, n = 7, with comparisons by paired t-test. (C) Recruitment
of mini-Gs (mGs) and β-arrestin-2 (βarr2) in response to 100 nM exendin-4, assessed by nanoBiT
complementation, n = 5, with AUC quantification and comparison by paired t-test. (D) cAMP responses
to exendin-4 in 293-T-REx-GLP-1R cells, normalised to 10 µM forskolin (FSK), n = 5, with pEC50 and
Emax compared by paired t-tests. (E) GLP-1R internalisation and uptake of exendin-4-C39-Cy5 uptake
in 293-T-REx-GLP-1R stimulated for 30 min, representative images of n = 3 experiments; scale bars
= 6 µm. (F) Quantification of GLP-1R internalisation and recycling by high content microscopy in
293-T-REx-GLP-1R cells, n = 5, with internalisation pEC50 and Emax compared by paired t-tests, and
recycling results compared by two-way randomised block ANOVA with Sidak’s test. (G) GLP-1R
degradation in 293-T-REx-GLP-1R cells stimulated with 100 nM exendin-4 and subsequently labelled
with BG-OG (0.5 µM), with representative images and quantification from n = 5 experiments, with t1/2
compared by paired t-test. * p < 0.05 by statistical test indicated. Data represented as mean ± SEM.
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Figure 5. GLP-1R structure and T149 structural role. (A) Surface representation of GLP-1R (in blue)
bound to exendin-P5 (in yellow) and guanine nucleotide-binding protein Gs subunit α (in cyan),
β (in salmon) and γ (in green). The intracellular and extracellular boundaries of the lipid bilayer are
presented as orange disks. T149 is coloured in red. (B) The intrahelical hydrogen bond formed by T149
(in red) is highlighted with black dashes. (C) Cartoon representation of GLP-1R structure highlighting
the juxta-membrane and intracellular region of TM1. The G protein subunits are also shown.
3. Discussion
In this study, we have examined factors that influence the post-endocytic fate of GLP-1R when
activated by two prototypical agonists for this receptor: GLP-1 and exendin-4. After first demonstrating
the effect of each agonist on GLP-1R recycling and degradation in a pancreatic beta cell context,
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we tested how these parameters are linked to resistance to proteolytic degradation, binding affinity
and recruitment of intracellular effectors. We also performed studies using a natural GLP-1R variant,
T149M, which showed attenuated signalling and internalisation responses to exendin-4, but faster
recycling and slower degradation. The key findings from our study are summarized in Figure 6.
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Increasing interest in how dynamic changes in GLP-1R subcellular localisation influence its ability
to promote downstream responses, such as insulin release, provides the context to this work. Like many
other GPCRs [43], entry into the endocytic pathway may be required for a full GLP-1R intracellular
signalling response [9,44]. However, with prolonged pharmacological stimulations, mounting evidence
from studies using biased agonists with distinctive GLP-1R trafficking characteristics [6,7,11,16,45]
suggests that preservation of a minimum level of surface-resident GLP-1R becomes a limiting factor for
insulin secretion. A fuller understanding of the range of factors influencing these processes is needed
so they can be optimally leveraged for therapeutic benefit.
etailed exa ination of GLP-1R trafficking is frequently conducted in non-beta cells [15,18],
and our work using beta cell models presents an environment more akin to that encountered by
GLP-1R in its native context. Here, we used primary islet cells to confirm extensive endocytic uptake of
both GLP-1 and exendin-4 in a “gold standard” model. However, as biorthogonal labelling of GLP-1R
in primary cells is currently not feasible, further studies to investigate the post-endocytic behaviours
of GLP-1R were performed using SNAP-tagged GLP-1R expressed in clonal beta cells. s expected,
both GLP-1 and exendin-4 induced pronounced GLP-1R internalisation, but with differences apparent
in subsequent recycling to the plasma membrane versus lysosomal degradation. To understand the
processes underpinning this divergence, we first built on recent work highlighting a potential role
for the endopeptidase ECE-1 in the control of GLP-1R trafficking [18], as previously shown for other
GPCRs [26,46]. We confirmed that GLP-1 (but not exendin-4) is a substrate for this enzyme at acidic
pH—a prerequisite for regulation of GLP-1R trafficking by endosomal ECE-1. We also demonstrated
that GLP-1-induced GLP-1R degradation in beta cells is modestly increased by ECE-1 inhibition.
However, this effect did not entirely explain the marked difference between GLP-1R degradation rates
observed with GLP-1 versus exendin-4, which might be due to the inco plete inhibition achieved in our
studies, reflect the activity of other endosomal endopeptidases not inhibited by SM-19712, or involve
further mechanisms unrelated to endopeptidase degradation of the ligand. Nevertheless, the potential
for therapeutic strategies based on ECE-1 inhibition [47] to affect the function of GLP-1R and other
peptide GPCRs as an unintended consequence should be borne in mind. It could further be envisaged
that GLP-1R ligands engineered for reduced resistance to ECE-1 might enhance plasma membrane
GLP-1R availability, thereby allowing longer-lasting insulinotropic responses through faster recycling.
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Designing such a peptide whilst maintaining an adequate degree of protection against extracellular
endopeptidases is, however, likely to be challenging.
Biased agonism can be leveraged to improve the therapeutic targeting of GPCRs,
including GLP-1R [5,48,49]. Here, we used biased GLP-1R ligands with N-terminal substitutions as
tool compounds to unpick the relative contributions of proteolytic stability from other pharmacological
parameters that control agonist-mediated GLP-1R degradation. From these studies, it was clear,
as expected, that many factors beyond resistance to ECE-1 influence how internalised GLP-1R agonists
can control the downstream fate of the receptor. Peptide variants with a phe1 or asp3 substitution
typically showed trafficking bias towards, respectively, recycling or degradation of the GLP-1R,
despite the sequence change being distant from the likely cleavage site for ECE-1. These differences
were frequently related to GLP-1R binding affinity, with high-affinity ligands showing a preference for
GLP-1R degradation. Differences in persistence of ligand-receptor complexes within the endosome are
likely to explain this association [50]. This rule did not universally apply; for example, exendin-phe1,
a biased ligand with promising anti-diabetic characteristics in vivo such as enhanced glucose lowering
and reduced nausea compared to exendin-4 [6], exhibited similar binding affinity to GLP-1 but yielded
considerably less GLP-1R degradation, even after differences in GLP-1R internalisation were taken into
account. GLP-1R degradation rates were also generally lower than predicted for asp3 substitutions
in exendin-4 and exendin-4-like peptides, opening the possibility, as previously shown for other
receptors [51–53], of the existence of alternative intracellular trafficking or sequestration behaviours of
the GLP-1R, e.g., to specialised non-degradative endosomal subpopulations. Overall, this series of
peptide agonists is a useful resource for the study GLP-1R trafficking, and could be used, for example,
to probe correlation of trafficking phenotypes with quantitative analyses of ligand-induced interactions
made by the receptor with candidate trafficking effectors.
Large population genomic studies have provided evidence of significant natural genomic
variability in GPCR coding sequences, which may partly underpin inter-individual responses to
therapeutic GPCR ligands [54]. In the present work, we studied the GLP-1R variant T149M, which is a
candidate risk allele for T2D [20], albeit with confirmation awaited from larger studies. Pharmacological
evaluations of this variant have consistently highlighted a pronounced signalling defect which does
not appear to result primarily from reduced expression or ligand binding [33,34,55]. In our hands,
GLP-1R T149M showed profoundly reduced recruitment of both mini-Gs and β-arrestin-2, with the
latter particularly attenuated. This pharmacological observation can be explained by the detrimental
effect of the T149M substitution on TM1 tilt and resultant disruption of the cytoplasmic regions required
for efficient coupling to G protein heterotrimers and β-arrestins. Moreover, GLP-1R internalisation
was also markedly reduced, although still detectable. The latter contrasts somewhat with a previous
study [34] in which no internalisation of the T149M GLP-1R variant could be observed with GLP-1
treatment, with this discrepancy probably reflecting differences in the ligands used in both studies.
We found that GLP-1R T149M recycles faster post exendin-4-induced internalisation, with an associated
slower rate of GLP-1R degradation. Interestingly, the combination of reduced β-arrestin-2 recruitment
efficacy, slower GLP-1R endocytosis but faster recycling and slower target receptor degradation,
recapitulates the pharmacological profile of stereotypical G protein-biased GLP-1R agonists such as
exendin-phe1 which, paradoxically, show increased insulinotropic efficacy. In the future, it may be
valuable to study this and other receptor variants in a beta cell environment to determine how coupling
efficiencies translate to insulin release.
Our study has a number of limitations. Firstly, experiments were in the most part conducted in
isolated clonal beta cells, which may not fully model the behaviour of fully differentiated primary beta
cells. Whilst we did make use of fluorescent ligands to confirm the basic endocytic profile of exendin-4
and GLP-1, following the agonist-directed intracellular journey of GLP-1R in a manner similar to our
use of SNAP-GLP-1R surface labelling is not easily achieved in primary beta cells, as specific GLP-1R
antibodies capable of labelling the extracellular receptor face compete with agonists for the orthosteric
binding pocket [56] and are therefore not suitable for these assays. Moreover, cell populations within the
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pancreatic islet are highly interconnected [57,58], and we did not perform comparative ligand uptake
studies with intact isolated islets or in vivo, as previously performed with fluorophore-conjugated
exendin-4 [15]. Our investigation into the role of ECE-1 was partially hampered by the fact that we
achieved only partial ECE-1 inhibition using a standard dose of the small molecule inhibitor SM-19712.
To avoid non-specific off-target effects from higher inhibitor concentrations, genetic approaches such
as CRISPR-Cas9 could be used to knock-out ECE-1 in clonal beta cells, or beta cell-specific ECE-1
knockout animals could be established to confirm whether this effect is physiologically important.
Finally, we included a single, rare GLP-1R variant in this report, with a reported minor allele
frequency of 1 × 10−5 [59]. Higher prevalence GLP-1R variants should be evaluated to provide a more
comprehensive picture of how genomic variation could impact on responses to therapeutic GLP-1R
agonists [54]. From the structural point of view, caveats apply to our models and interpretation as no
full-length exendin-4-bound GLP-1R structure is available, requiring us to rely on structural models
with alternative (albeit similar) orthosteric ligands bound.
The distinct trafficking phenotypes of GLP-1 versus exendin-4 are of potential clinical
importance as approved GLP-1R agonist treatments are essentially derivatives of these two peptides.
Liraglutide, Semaglutide, Dulaglutide and Albiglutide share a high degree of homology with GLP-1,
whereas Exenatide and Lixisenatide are, respectively, identical or highly similar to exendin-4. It might
be expected that these ligands will show differences in their trafficking phenotypes, and indeed this
appears to be the case [6]. However, the impact of the conjugated acyl chain (Liraglutide, Semaglutide),
Fc fragment (Dulaglutide) or albumin moiety (Albiglutide) beyond that of the peptide itself is not
clear, with recent work highlighting how acylation can protect GLP-1R agonists from degradation by
NEP24.11 [30].
In summary, this work demonstrates how ligand-, cell- and receptor-specific factors can influence
the post-endocytic sorting of GLP-1R, providing an opportunity to optimise the therapeutic potential
of this treatment class.
4. Materials and Methods
4.1. Reagents
Custom peptides were purchased from Wuxi Apptec (Shanghai, China) and were at least 90%
pure. Synthesis of exendin-4-Cy5 is described in Supporting Information (Supplementary Methods).
SNAP-Surface probes were purchased from New England Biolabs (Ipswich, MA, USA). BG-S-S-649 [11]
and BG-S-S-biotin [6] were provided by New England Biolabs on a collaborative basis. BG-OG has
been previously described [24]. The source of other reagents is described in the relevant sections.
4.2. Plasmids
pSNAP-GLP-1R was obtained from Cisbio (Codolet, France). FLAG-GLP-1R-SmBiT was generated
as previously described [7]. The plasmid for mini-Gs carrying an N-terminal LgBiT tag [35] was a
gift from Prof Nevin Lambert, Medical College of Georgia. The plasmid for β-arrestin-2 fused
at the N-terminus to LgBiT (plasmid CS1603B118) was obtained from Promega custom assay
services (Madison, WI, USA). Custom GLP-1R expression plasmids, wild-type and T149M mutant
pcDNA5-SNAPf-GLP-1R-SmBiT, were generated by Genewiz (Leipzig, Germany) to the following
design: codon-optimised wild-type or T149M variant human GLP-1R (lacking the endogenous
N-terminal signal peptide) was tagged at the N-terminus with a fast-labelling SNAPf tag and upstream
signal peptide based on that of the 5-HT3A receptor (MDSYLLMWGLLTFIMVPGCQA), plus C-terminal
SmBiT tag, and inserted into the pcDNA5/FRT/TO expression vector. pOG44 was obtained from Thermo
Fisher (Waltham, MA, USA).
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4.3. Cell Culture
INS-1-SNAP-GLP-1R cells, generated by stably expressing pSNAP-GLP-1R in INS-1 832/3 cells
lacking endogenous GLP-1R expression after deletion by CRISPR/Cas9 (a gift from Dr Jacqueline
Naylor, AstraZeneca) [60], have been previously described [23] and were maintained in RPMI-1640 with
11 mM glucose, 10 mM HEPES, 2 mM glutamine, 1 mM sodium pyruvate, 50 µM β-mercaptoethanol,
10% foetal bovine serum (FBS), 1% penicillin/streptomycin and 1 mg/mL G418. MIN6B1-SNAP-GLP-1R
cells [10], derived from the parental MIN6B1 subline [61] (a gift from Prof Philippe Halban, University
of Geneva), were maintained in DMEM supplemented with 50 µM β-mercaptoethanol, 15% FBS,
1% penicillin/streptomycin and 1 mg/mL G418. HEK293T and Flp-In™T-REx™ 293 cells (Thermo Fisher)
were maintained in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. To obtain
populations of isogenic SNAP-GLP-1R-SmBiT and SNAP-GLP-1R-T149M-SmBiT expressing cells,
T-REx-293 cells were co-transfected with pOG44 and pcDNA5-SNAPf-GLP-1R-SmBiT or SNAPf-GLP-1R
T149M-SmBiT in a 9:1 ratio, followed by selection with 100 µg/mL hygromycin.
4.4. Fluorescence Imaging of Fixed Samples
Cells grown on poly-D-lysine-coated coverslips were fixed with 4% paraformaldehyde for 15 min
at room temperature, washed, and mounted onto slides in Diamond Prolong anti-fade with DAPI
(Thermo Fisher). Imaging was performed using a Nikon Ti2-E microscope controlled by custom
scripts [62] implemented in µManager [63], with an LED light source (CoolLED). Z-stacks were
acquired at 100× using a 1.45 numerical aperture oil immersion objective and were deconvolved with
DeconvolutionLab2 [64] in Fiji (v1.53a) using the Richard-Lucy algorithm.
4.5. Electron Microscopy
MIN6B1-SNAP-GLP-1R cells were seeded onto Thermanox coverslips (Agar Scientific, Essex, UK),
labelled with 2 µM cleavable BG-S-S-biotin surface SNAP-tag probe at 37 ◦C for 30 min and secondarily
labelled with 5 µg/mL AlexaFluor 488 Streptavidin conjugated to 10 nm colloidal gold. Cells were
stimulated with 11 mM glucose plus 100 nM agonist for 1 h, fixed with 2% PFA + 2% glutaraldehyde in
0.1 M cacodylate buffer for 30 min at room temperature, washed with phosphate buffer and prepared
for conventional EM. Cells were post-fixed in 3% potassium ferricyanide + 2% osmium tetroxide
and treated with tannic acid followed by dehydration with increasing concentrations of ethanol and
propylene oxide, embedded in Epon resin and mounted onto Epon stubs. Epon was polymerised
overnight at 60 ◦C and coverslips removed by surface heating. Ultrathin 70 nm sections were cut with
a diamond knife on a Leica ultramicrotome, stained with 2% uranyl acetate, visualised in a Tecnai T12
Spirit transmission electron microscope with a CCD camera and analysed in ImageJ (v1.52).
4.6. Fluorescent GLP-1R Ligand Uptake Assay in Primary Dispersed Pancreatic Islets
Pancreatic islets were isolated from GLP-1R-iCre-GCaMP3 mice (9–13 weeks old), a mouse
strain in which GCaMP3 is restricted to cells with GLP-1R promoter activity [22]. Pancreata were
inflated with RPMI-1640 medium containing 1 mg/mL collagenase from Clostridium histolyticum
(S1745602, Nordmark Biochemicals, Germany), dissected and incubated in a water-bath at 37 ◦C for
12 min. Islets were subsequently washed and purified using a Histopaque gradient (Histopaque-1119
and -1083). Isolated islets were allowed to recover overnight in RPMI-1640 supplemented with 10%
and 1% penicillin/streptomycin. Islet dispersal was achieved by trituration in 0.05% trypsin-EDTA
at 37 ◦C for 3 min, followed by trypsin inactivation with complete medium. Dispersed islet cells
were then seeded onto poly-D-lysine-coated coverslips and allowed to adhere overnight in complete
RPMI-1640. The following day, 100 nM GLP-1R-TMR, exendin-4-TMR, or vehicle were added to the
well, and incubated for 30 min at 37 ◦C. Medium was then removed, and cells were washed once with
HBSS and fixed with 4% PFA for 15 min. Washed coverslips were subsequently mounted onto glass
slides in Prolong Diamond anti-fade with DAPI (Thermo Fisher).
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4.7. High Content Imaging Internalisation and Recycling Assay
INS-1-SNAP-GLP-1R cells in complete medium, or T-REx-SNAP-GLP-1R-SmBiT cells in complete
medium ± 0.1 µg/mL tetracycline, were seeded in poly-D-lysine-coated black, clear-bottom plates.
Medium was removed and cells labelled with 0.5 µM BG-S-S-649 in complete medium for 20–30 min at
37 ◦C. After washing three times in HBSS, cells underwent fluorescence imaging to establish the baseline
labelling. A 0.75 numerical aperture 20× phase contrast objective was used to acquire epifluorescence
and transmitted phase contrast images, with 9 fields-of-view (FOVs) per well. Agonists were then
applied in serum-free medium at the indicated dose for a 30 min stimulation period to induce
GLP-1R internalisation. Cells were then washed with HBSS, followed by a 5 min treatment ± 100 mM
sodium 2-mercaptoethanesulfonate (Mesna) in alkaline TNE buffer (pH 8.6) to cleave residual surface
BG-S-S-649 without affecting that internalised whilst bound to SNAP-GLP-1R, re-washed and re-imaged.
After a further 60 min recycling period in serum-free medium, a second Mesna treatment was
applied to remove any labelled receptor recycled to the cell surface, then cells were washed and
re-imaged. Flat-field correction of epifluorescence images was performed using BaSiC [65] and cell
segmentation was performed using PHANTAST for the phase contrast image [66]. For quantification
of “mean cellular fluorescence intensity”, mean background per image was determined from the
segmented epifluorescence image and subtracted from the mean fluorescence intensity from the
cell-containing regions. Normalised intensities at internalisation and recycling time-points were
expressed as a percentage of the mean intensity at baseline after subtraction of the signal from
vehicle-treated cells exposed to Mesna, to establish the degree of specific agonist-induced endocytosis.
This was quantified by 3-parameter fitting in Prism 8.0 (Graphpad Software, San Diego, CA, USA)
where relevant. Recycling was calculated as the percentage difference between internalisation and
recycling time-points.
4.8. SNAP-GLP-1R Degradation Assay by Microscopy
INS-1-SNAP-GLP-1R cells were seeded in complete medium in poly-D-lysine-coated black,
clear-bottom plates. Medium was removed, cells were washed twice and fresh serum-free medium
containing cycloheximide (50 µg/mL) to arrest protein translation was applied. 2 h later, agonists were
added in reverse time order, with the medium replaced for the final 30 min of the experiment
with complete medium containing 1 µM BG-OG to label total residual SNAP-GLP-1R. Wells were
then washed 3 times with HBSS and the microplate was imaged as described in Section 4.7 using
a green fluorescence filter set. For T-REx-SNAP-GLP-1R cells, the assay was performed similarly,
except cells were seeded in complete medium ± 0.1 µg/mL tetracycline for 18 h to induce GLP-1R
expression, which was then removed 2 h prior to the assay to prevent ongoing GLP-1R synthesis.
For pulse-chase experiments using INS-1-SNAP-GLP-1R cells, cycloheximide (50 µg/mL) was applied
two hours before agonist addition and throughout thereafter. Agonists were applied for 30 min
and removed with washing, followed by a 4 h washout period and a 30 min labelling period
in complete medium containing 1 µM BG-OG, prior to washing and imaging as in Section 4.7.
Where relevant, ECE-1 inhibitor SM-19712 (10 µM; Sigma, St Louis, MO, USA) was supplemented for
the duration of the washout period. Total GLP-1R was quantified as the mean cellular fluorescence
labelling per well (as defined in Section 4.7), with further subtraction of non-specific fluorescence
(i.e., INS-1-SNAP-GLP-1R cells without BG-OG labelling, or T-REx-SNAP-GLP-1R cells labelled with
BG-OG but without tetracycline-induced GLP-1R expression). Results were expressed relative to
labelled cells without agonist treatment. Time-courses were quantified by calculating the degradation
t1/2 from one-phase decay exponential curve fitting using Prism 8.0. Pulse-chase experiments were
further quantified by 3-parameter fitting of concentration-response data using Prism 8.0.
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4.9. SNAP-GLP-1R Degradation Assay by Immunoblotting
INS-1-SNAP-GLP-1R cells (1.5 million per dish) were cultured overnight prior to incubation in
serum-free medium containing cycloheximide (50 µg/mL) supplemented or not with 10 nM agonist
for 6 h. Cells were then washed once in cold PBS and lysed with 1× TNE lysis buffer (20 mM Tris,
150 mM NaCl, 1 mM EDTA, 1% NP40, protease and phosphatase inhibitors) for 10 min at 4 ◦C.
The lysates were then frozen at −80 ◦C for 2 min, thawed and centrifuged for 10 min at 4 ◦C at
13,000 rpm. Supernatants were collected, fractionated by SDS-PAGE in urea loading buffer and
analysed by western blotting. SNAP-GLP-1R was detected with an anti-SNAP tag rabbit polyclonal
antibody (P9310S, New England Biolabs, 1/500) followed by goat anti-rabbit IgG H&L HRP (1/2000,
ab6271, Abcam, Cambridge, UK). Post-stripping, tubulin was labelled with anti-α-tubulin mouse
monoclonal antibody (T5168, Sigma, 1/5000) followed by sheep anti-mouse secondary antibody HRP
(ab6721, Abcam, 1/5000). Blots were developed with the Clarity™Western ECL Substrate (BioRad,
Hercules, CA, USA) in a Xograph Compact X5 processor and specific band densities quantified in Fiji.
4.10. Measurement of Binding Affinities
Competition equilibrium binding assays were performed in whole HEK293-SNAP-GLP-1R
cells. Cells were labelled with Lumi4-Tb (Cisbio, 40 nM) for 30 min at 37 ◦C in complete medium.
After washing 3 times in HBSS, labelled cells were resuspended in HBSS containing 0.1% BSA, along with
metabolic inhibitor cocktail (20 mM 2-deoxyglucose plus 10 mM NaN3) to inhibit ATP-dependent
endocytosis, as previously described [67], and dispensed into white 96-well plates. After a 30 min
preincubation at room temperature, cells were moved to 4 ◦C before agonist addition. Each experiment
included a range of concentrations of the fluorescent antagonist probe exendin (9-39)-FITC [12],
along with a range of concentrations of unlabelled test agonists in competition with 10 nM exendin
(9-39)-FITC. After a 24 h incubation at 4 ◦C to reach equilibrium binding, the plate was read by
TR-FRET in a Flexstation 3 instrument using the following settings: λex = 340 nm, λem = 490 nm
(cut-off 475 nm) and 520 nm (cut-off 515 nm), delay 50 µs, integration 300 µs. Saturation Kd for
exendin (9-39)-FITC from ratiometric TR-FRET data was established using the “one site–specific
binding” algorithm in Prism 8.0 and was used on a per assay basis to determine Ki for each test
agonist though the “one site–fit Ki” algorithm. Kinetic binding assays were performed in wild-type
and T149M variant T-REx-SNAP-GLP-1R cells after overnight induction of receptor expression using
tetracycline (0.1 µg/mL). Cells were labelled and resuspended in HBSS containing BSA and metabolic
inhibitors as above. After a 5 min baseline read, a range of concentrations of exendin-4-Cy5 were
added and binding was monitored in real time at 37 ◦C by TR-FRET in a Flexstation 3 instrument
using the following settings: λex = 340 nm, λem = 490 nm (cut-off 475 nm) and 668 nm (cut-off 630 nm),
delay 50 µs, integration 300 µs. Baseline TR-FRET ratio was subtracted from each well and curve fitting
was performed to calculate binding kinetic parameters using the “2 or more concentrations of hot”
procedure in Prism 8.0.
4.11. NanoBiT Assays
To measureβ-arrestin-2 recruitment to GLP-1R, HEK293T cells in 12-well plates were co-transfected
for 24 h using Lipofectamine 2000 and the following quantities of DNA: 0.05 µg each of GLP-1R-SmBit
and LgBit-β-arrestin-2 with 0.9 µg empty vector DNA (pcDNA3.1). For experiments using stably
transfected T-REx-SNAP-GLP-1R cells, 0.2µg LgBit-β-arrestin-2 with 1.8µg pcDNA3.1 were transfected
per well of a 6-well plate for 36 h, with wild-type or T149M variant receptor expression induced for
the final 24 h using tetracycline (0.1 µg/mL). Cells were resuspended in Nano-Glo dilution buffer +
furimazine (Promega) diluted 1:20 and seeded in 96-well half area white plates. Baseline luminescence
was measured over 5 min using a Flexstation 3 plate reader at 37 ◦C before addition of ligand or vehicle.
After agonist addition, luminescent signal was serially recorded over 20–30 min and normalised to
well baseline and to average vehicle-induced signal to establish the agonist effect.
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4.12. Cyclic AMP Assay
Wild-type or T149M variant GLP-1R expression was induced in T-REx-SNAP-GLP-1R cells by
addition of tetracycline (0.1 µg/mL) for 24 h prior to the assay. Cells were treated with a range of
concentrations of exendin-4 for 30 min at 37 ◦C in serum-free DMEM. cAMP was determined by HTRF
(Cisbio cAMP Dynamic 2 assay). Curve fitting and bias analysis was performed using Prism 8.0.
4.13. Measurement of ECE-1 Activity
ECE-1 activity from INS-1-SNAP-GLP-1R cell lysates was measured using a fluorometric assay
(ECE-1 Activity Assay, Promocell, Germany). Lysates prepared from INS-1-SNAP-GLP-1R cells grown
in 6-well plates using the provided lysis buffer were diluted 1:5 and ECE-1 activity was determined in
duplicate according to the manufacturer’s instructions in the presence or absence of 10 µM SM-19712.
Measured activity was expressed relative to sample protein content determined by the BCA assay.
4.14. Measurement of Peptide Stability by HPLC
10 nmol GLP-1 or Ex-4 were dissolved in 750 µl ECE buffer (0.2 M Acetate acid buffer, pH 5.5).
0.25 µg recombinant ECE-1 (R&D Systems), or no enzyme as a control for non-enzymatic degradation
over the same time period, was added to the reconstituted peptide. Reactions were incubated at
37 ◦C and 120 µL samples were collected from the reaction vessel at the indicated time-points.
5 µL 10% trifluoroacetic acid (TFA) was added to each sample to terminate enzyme activity.
Samples were analysed by reverse-phase high-performance liquid chromatography (HPLC) with a
linear acetonitrile/water gradient acidified with 0.1% TFA on Phenomenex Aeris Peptide 3.6 µm XB-C18
Column (150 × 4.6 mm). The eluted peptides were detected at 214 nm. Degradation of peptide was
calculated by comparing the area under the peak of the original compound with and without enzyme.
4.15. Structural Analysis
The experimental structures of GLP1R were extracted from ProteinDataBank (PDB). The following
structures were considered for analysis: 6B3J, 5VAI, 5E94, 5NX2, 3C5T, 3C59, 3I0L, 4ZGM. Using the first
two of this list [38,68], mutant GLP-1R structures (GLP-1R-T149M) were generated using an in-house
algorithm, as described in Reference [69], and compared to that obtained using another modelling
tool, FoldX [70]. Additionally, the experimental structure of β-arrestin-1 bound to the β1-adrenergic
receptor [40] was retrieved (PDB ID: 6TK0). The experimental structure of GLP-1R (PDB ID: 6B3J)
was superposed to that of the β1-adrenergic receptor and the position of β-arrestin-1 inherited.
Manual analysis was performed to assess the following structural features in the wild-type and
mutant GLP-1R structure: disulphide bond breakage, steric clash, hydrogen bond breakage, salt bridge
breakage, cavity alteration, disallowed phi/psi angles and secondary structure change, as detailed in
Reference [69]. For transmembrane (TM) residues, the following structural features were considered:
hydrophilic to hydrophobic switch, to proline substitution, charge introduction, charge switch and
glycine replacement. Residues and physico-chemical bonds contributing to GLP-1R binding to its
ligands were identified using the approach described in Reference [71]. The stability of the wild-type
and mutant GLP-1R protein was assessed by calculating the protein-free energy (∆G, in kcal/mol)
using the FoldX algorithm. The amino acid substitution was considered to significantly affect the
stability of GLP-1R if the difference in free energy (∆∆G) between the mutant and wild-type structure
was >1 kcal/mol, with ∆∆G > 0 kcal/mol considered destabilising and ∆∆G < 0 kcal/mol stabilizing.
An in-house algorithm was used to place the GLP-1R protein structure within the lipid bilayer.
4.16. Data Analysis and Statistics
All quantitative data were analysed using Prism 8.0. The indicated n refers to the number
of independent biological replicates. Technical replicates within the same assay were averaged to
determine the mean value for each biological replicate. For experiments with a matched design,
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paired two-tailed t-tests or randomised block analysis of variances (ANOVAs) were performed.
Specific statistical tests are indicated in the figure legends. Statistical significance was inferred when
p < 0.05 without ascribing initial levels of significance at lower p-values. Principal component analysis
was performed using ClustVis [72] with unit variance scaling applied. Data are represented throughout
as mean ± standard error othe mean (SEM), with results from individual biological replicates presented
where possible.
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